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ABSTRACT 
Oncology pharmacy service was developed and 
integrated into the multidisciplinary team of oncology clinic 
in 2013 at the United Christian Hospital aiming to enhance 
the holistic patient-centre practice of the clinic through the 
optimization of the safety and efficacy of anti-cancer 
treatment. This review aims to describe the role and impact 
of oncology pharmacists (OPs) in clinical setting to optimize 
anti-cancer treatment for cancer patients in a 
multidisciplinary care approach. From selection, 
prescribing, procurement to monitoring and patient 
education, OPs significantly contribute to the safety and 
effective use of anti-neoplastics in any circumstances. OPs 
provide professional advices to oncologists in choosing the 
appropriate anti-cancer agents for specific cancer and 
designing personalized anti-cancer treatment according 
to patients’ fitness and appropriateness for chemotherapy. 
Parenteral and oral chemotherapeutic agents carry 
heightened risk of causing significant patient harm when 
they are used in errors. Thus, OPs also develop standardized 
chemotherapy orders and ensure the final dose is 
appropriate in terms of both haematological and non-
haematological responses and tolerability. Moreover, OPs 
play an important role in procuring anti-cancer drugs and 
sourcing alternative drug choices that will deliver similar 
clinical outcomes. In addition, OPs also assure the clinical 
integrity of anti-cancer drugs for full anti-neoplastic activity 
and safe administration of these drugs by nursing staff to 
minimize potential occupational risk. Most importantly, OPs 
play a vital role in providing direct patient care functions 
such as drug therapy monitoring and management (e.g. 
ensure that patients receive sufficient pre-medications for 
administration of anti-cancer drugs), and medication 
counselling for patients and their carers to better 
understand their anti-cancer treatment. The positive 
impact of integrating OPs into the multidisciplinary patient-
centre practice of oncology clinic includes (1) reduction in 
potentially life-threatening medication incidents and 
cancer drug administration errors in public hospitals; (2) 
collaboration with oncologists to select the most suitable 
cancer drug regimens for patients; (3) prevention of 
potential occupational risk to the healthcare professionals 
who handle cancer drugs; and (4) provision of optimal 
therapy treatment, monitoring and counselling to patients 
to reduce side effects and hospital readmission. The 
professional drug knowledge of OPs adds value to the 
multidisciplinary team in oncology clinics and the growth of 
OPs into effective direct patient care in oncology clinics 
should be encouraged to optimize medication-related 
outcomes. 
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INTRODUCTION 
In Hong Kong, anti-cancer agents including both 
parenteral and oral agents are classified as high-alert 
medication in public sector, meaning they bear 
heightened risk of causing significant patient harm when 
they are used in errors. [1] Endeavour had therefore been 
made to avoid potential life-threatening incidents involving 
the anti-cancer agents. Since the role of clinical 
pharmacists has been well established and described in 
overseas setting in reducing medication errors [2-6], 
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oncology clinical pharmacy service was developed to 
optimize the use of chemotherapy in Hong Kong.  
 
This descriptive review paper focuses on the oncology 
pharmacists’ (OPs) role from a viewpoint of clinical 
practice in an oncology centre of a public hospital in Hong 
Kong in various components of medication management, 
outlined by the Joint Commission (the accreditation body 
for health care facilities in the US): 1) selection; 2) 
procurement; 3) prescribing, dosing and transcribing; 4) 
storage; 5) preparing and dispensing; 6) administering; and 
7) monitoring and evaluation, and 8) patient education. [7] 
 
SELECTION 
Oncology pharmacists can aid in selecting the appropriate 
anti-cancer agents for the specific cancer through 
providing up-to-date medical information. Oncologists 
often consult OPs for adverse effect profiles and 
contraindications. For instance, renal patients on renal 
replacement therapy such as peritoneal dialysis who are 
going to receive chemotherapy, OPs would discuss with 
oncologists to select the most appropriate regimen that are 
less renally excreted and recommend an appropriate dose 
based on the renal function. [8] More importantly, OPs 
would assist oncologists to design the administration 
schedule according to the dialysability of the prescribed 
regimen to optimize the treatment outcome. OPs perform 
drug information and literature search to provide 
recommendation of combination of drugs in certain 
diseases based on efficacy and safety concerns. OPs may 
also provide information on adverse effects of drugs once 
the oncologists suspect drug-induced problems, which aid 
oncologists to change and select the appropriate 
alternative anti-cancer agents. 
 
During clinical screening for patients on fitness and 
appropriateness for chemotherapy, OPs often take into 
account the previous history of chemotherapy, if any, and 
the concurrent medication that the patient is taking. In 
particular, OPs calculate the cumulative anthracycline 
dose that the patient has taken and inform oncologists 
when the cumulative dose would be exceeded. [9-10] OPs 
collaborate with oncologists to select the appropriate 
medication in cancer treatment to reduce adverse effects 
that could happen. 
 
Since the introduction of targeted therapy, efforts have 
been made to further identify the potential molecular 
targets for drug development. Response to targeted 
therapy also depends on the existence of specific gene  
mutation. OPs can aid in selecting the appropriate 
targeted therapy by screening the existence of the 
mutated genes and ensure the appropriate therapy is 
prescribed. For example, OPs would advise against the use 
of erlotinib or gefitinib in non-small cell lung cancer patients 
who acquire T790M mutation of the epidermal growth 
factor receptor (EGFR). [11] OPs also ensure that metastatic 
colorectal cancer patients receiving cetuximab, a 
recombinant human/mouse chimeric monoclonal 
antibody that binds specifically to the epidermal growth 
factor receptor (EGFR, HER1, c-ErbB-1), are K/N-RAS wild 
type for the optimal treatment outcome.  
 
PROCUREMENT 
Making a drug available to the patient is certainly an 
essential step of pharmaceutical care. In case of drug 
shortages, OPs in Hong Kong play an important role in 
looking for alternatives of anti-cancer treatment. This may 
include the same drug entity with alternative drug sources 
or a completely different drug entity. When looking for 
drugs of an intrathecal treatment with different drug 
sources, OPs would pay particular attention to the 
formulation if it contains preservatives. Besides, drugs from 
different drug sources may require different reconstitution 
methods and have different volumes after reconstitution. 
This may affect the volume to be injected intrathecally and 
require careful clinical assessment. OPs would hence 
communicate closely with oncologists to avoid 
unintentional clinical incidents. If an alternative drug entity 
is required, OPs may need to perform dosage conversion 
involving anthracyclines to assess the cumulative dose 
administered. To enhance patient adherence and clinical 
outcome, OPs are also responsible for identifying drugs with 
suitable dosage form for medical conditions that could 
complicate anti-cancer treatment. Magnesium trisilicate 
had once been used for oral magnesium supplementation 
in patients experiencing hypomagnesemia in our hospital. 
OPs have worked to look for magnesium tablets which aid 
better absorption of magnesium to improve 
supplementation needs. Besides, folic acid solution had 
been used for low-dose supplementation in patients 
receiving pemetrexed until OPs sought out folic acid tablet 
with a smaller strength. This also improves patient 
convenience in administering the medication. 
 
Oncology Pharmacist’s Role and Impact on the Multidisciplinary Patient-Centre Practice of Oncology Clinic in Public Hospitals in Hong Kong 3 
Asia Pacific Journal of Health Management 2019;14(1):i203.  doi: 10.24083/apjhm.v14i1.203 
Not only newer anti-cancer drugs are increasingly 
available, but also are newer chemotherapy supportive 
medications. Newer anti-emetics are developed to 
improve patient adherence through combining more than 
one class of medications in one pill and simplifying the 
regimen into single dose instead of short courses of multiple 
doses. OPs may work with oncologists for the availability of 
newer chemotherapy supportive medication in local 
hospitals to enhance patient convenience and hence 
treatment outcome. 
 
PRESCRIBING, DOSING, AND TRANSCRIBING 
Prescribing chemotherapy is a complex process involving 
not only the appropriate combination of drug entities but 
also the appropriate scheduling, dosing and route of 
administration. Error rates in chemotherapy have been 
reported at 3%–16%. [12-13] Standardized medication 
administration records (MARs) can reduce transcribing and 
interpretation errors and hence minimize medication errors 
that could be potentially life-threatening. [14] These 
standardized order components include diagnosis, height 
and weight and with the calculated body surface area 
(BSA), drug allergy status, dosage (mg/m2 or mg/kg) with 
final calculated dose, start date and day of therapy, 
diluent solution and volume, infusion rate, route 
(intravenous [IV] bolus, IV infusion, subcutaneous, 
intramuscular or intrathecal) and the total number of 
scheduled doses. In our institution, standardized orders are 
designed by OPs which also consist of preventive anti-
emetic medications, hydration protocols and other 
essential pre-medications required. Standardized drug set 
in the electronic prescribing system is also designed to 
facilitate prescribing chemotherapy and supportive care 
medications by oncologists. 
 
At the prescribing level, oncology pharmacists also screen 
for concurrent medical conditions that require 
pharmacological therapy. One particular concern in 
patients receiving chemotherapy is the reactivation of 
hepatitis B infection. In Hong Kong, the prevalence of 
hepatitis B carrier is around 5-10%. [15] OPs would screen for 
HBsAg and anti-HBc to identify patients at high risk of 
hepatitis B reactivation and ensure pre-emptive anti-viral 
treatment is given prior to initiation of chemotherapy if 
necessary. [16-17] To prevent herpes zoster reactivation, 
OPs would also recommend initiating antiviral prophylaxis 
such as acyclovir before starting bortezomib or 
daratumumab for multiple myeloma patients and 
throughout the treatment.  
 
Drug-drug and drug-disease interactions influence the 
choice of anti-cancer drugs and the interacting drugs as 
well. Certain selective serotonin reuptake inhibitors (SSRIs) 
such as fluoxetine and paroxetine are well known CYP2D6 
inhibitors which reduce the activation of tamoxifen to a 
more active metabolite, diminishing the anti-cancer effect. 
This may require modification of either the anti-cancer 
therapy or anti-depressants. OPs also exercise caution on 
prescribing injectable anti-androgens in prostate cancer 
patients who are concurrently taking anticoagulants as 
some injectable anti-androgens require intramuscular 
administration which is not preferred in patients on 
anticoagulants. Besides, OPs advise on the possibility of 
vaccination before and after the initiation of 
chemotherapy especially the administration of live 
attenuated vaccines.  
 
Immunotherapy which triggers the immune system to 
attack tumour cells is a major advance in anti-cancer 
treatment in recent years. [18] Although it gives promising 
results in terms of disease progression and survival benefit 
[19-25], some patients may experience rare but potentially 
life-threatening immune-related adverse effects such as 
pneumonitis, thyroiditis and hepatitis. [26] Therefore, OPs 
would assure baseline monitoring of thyroid function, chest 
X-ray (CXR), liver function and other related parameters to 
be done before prescribing immunotherapy.  
 
Dosing in chemotherapy requires careful calculation since 
some drugs such as cisplatin and pemetrexed may utilize 
the body surface area while some others such as 
trastuzumab may utilize the body weight. In calculating the 
dose for carboplatin, Calvert formula composing of the 
prescribed AUC and the creatinine clearance based on 
the Cockcroft-Gault Equation is used. [27] OPs play a major 
role in verifying the final dose given to the patients and 
ensure the dose prescribed does not exceed the capped 
dose. OPs also ensure the dose to be delivered is 
appropriate for renal and liver patients. If required, OPs 
would recommend dosing adjustment according to organ 
dysfunction. Besides, OPs would assess the dosing 
appropriateness based on patient’s tolerability. Patients 
who experienced profound haematological toxicities may 
require dose adjustment in the next cycles. Significant non-
haematological toxicities such as dermatological toxicities 
may also warrant adjustment to improve patient’s 
tolerance.  
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STORAGE 
Proper storage conditions with respect to temperature and 
lighting are essential in maintaining the chemical integrity 
of anti-cancer drugs for full anti-neoplastic activity. By 
taking reference to the manufacturer’s recommendation 
and available drug information, OPs establish the required 
conditions of the reconstituted anti-cancer drugs for 
storage and transport. If stability data is not available for 
certain preparation of anti-cancer drugs, pharmacists may 
liaise with local laboratory to produce the relevant stability 
data for consideration. Besides, pharmacists are 
responsible for tackling look-alike and sound-alike (LASA) 
issues to avoid potential dispensing errors. For example, 
rituximab for IV infusion and for subcutaneous injection 
have similar packaging and require separate physical 
storage to avoid inadvertently incorrect picking. Tall-man 
lettering in the drug labels on the shelves and other auxiliary 
labels are also designed to differentiate between LASA 
drugs by highlighting the main difference in the drug 
names.  
 
PREPARATION AND DISPENSING 
Cytotoxic nature of anti-cancer drugs does not only cause 
patient harm if misused but also imposes potential 
occupational risk to the healthcare professionals who 
handle these drugs. To minimize systemic exposure to the 
handling personnel, reconstitution of products is best 
prepared in aseptic environment with the use of isolators. 
[28] OPs are responsible for designing standardized 
compounding worksheets and the effective workflow 
within the aseptic area that would allow timely preparation 
of cytotoxic drugs without compromising the quality. In 
particular, OPs would make sure no reconstitution of LASA 
drugs to be done simultaneously to avoid incidental 
preparation of wrong drugs. In our hospital, reconstitution 
of subcutaneous injection and intravenous infusion of 
trastuzumab are done in separate sessions, for example, 
one in the morning session while the other in afternoon 
session. OPs are also responsible for training competent 
pharmacy personnel to perform aseptic reconstitution. 
More importantly, OPs would assure the aseptic facility 
compliance with relevant regulatory standards and ensure 
safety to both pharmacists and pharmacy personnel as 
well as the sterility of finished products. 
 
 
 
OPs ensure that the reconstitution of anti-cancer treatment 
follows manufacturer’s recommendation to maintain the 
sterility and stability in order not to compromise the quality 
and effectiveness of anti-cancer drugs. Drug compatibility 
is one of the determinants of the physical and chemical 
properties of anti-cancer drugs. OPs recommend the 
proper diluent and material of container for preparation of 
anti-cancer drugs. For example, paclitaxel and docetaxel 
are incompatible with PVC and non-PVC bags are required 
to maintain the anti-neoplastic activity. OPs also ensure 
that light-sensitive drugs are prepared in light-protected 
bags. OPs also determine the expiry date on the final 
products by taking into account the manufacturer’s 
recommendation and the available local laboratory 
testing results. 
 
To facilitate safe administration of chemotherapy by 
nursing staff to the patients, OPs ensure the products are 
properly prepared and packaged. The final products are 
properly labelled and relevant auxiliary labels are affixed to 
remind nursing staff. Incidents involving misadministration of 
intrathecal vinca alkaloids had been reported worldwide. 
[29-31] Labels with ‘For intravenous use only. Fatal if given 
other route.’ are stuck onto the outer package of the 
products to further alert the use of proper route. Besides, 
vinca alkaloids must be prepared in at least 100ml infusion 
bags for adults to avoid intrathecal administration. In our 
institution, pharmacy personnel is responsible for 
connecting the infusion set to the infusion bags to minimize 
the risk of spillage in clinical area. Finished products would 
be packed in double-bag and properly sealed to reduce 
over-spillage if leakage happens. Moreover, OPs would 
ensure transportation of anti-cancer drugs is carried out 
safely. The anti-cancer drugs are transported in a 
designated container and must be accompanied by 
spillage kit to allow timely management of cytotoxic 
spillage by trained personnel. Cold-chain system is also 
strictly maintained during transportation by insulated cold 
packs.    
 
ADMINISTRATION 
Oncology pharmacists often receive questions on the 
injectable drug compatibilities with multiple infusion lines 
and administration sequencing from nurses. Increased 
availability of newer treatment has diversified anti-cancer 
therapy and patients may receive chemotherapy, 
targeted therapy and immunotherapy in the same 
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regimen. OPs provide recommendation on the sequencing 
of drug administration to optimize the outcome of anti-
cancer therapy.  OPs provide evidence-based information 
to ensure safe and effective administration of cytotoxic 
drugs. Besides, extravasation kits and protocols are 
established to guide nursing staff to the appropriate 
management of extravasation of different drugs. 
 
Oncology Pharmacists also design standardized 
medication administration form (MARs) for chemotherapy 
to aid the administration of the anti-cancer drugs and their 
supportive medications. Regimen consisting of 
conventional chemotherapy causes emesis to different 
extent. Combination of different classes of anti-emetic 
drugs decreases episodes of nausea and vomiting and 
hence enhances patients’ quality of life and tolerability to 
cycles of anti-cancer treatment. OPs assess the 
emetogenicity of the anti-cancer treatment and 
standardize the use of anti-emetics for different regimens in 
the standardized MARs. This facilitates the administration of 
chemotherapy by reducing acute and delayed episodes 
of emesis. Besides, hydration protocols and pre-
medications required are also included in the standardized 
MARs. For example, in the regimen consist of pemetrexed 
and cisplatin, pre-medication of dexamethasone and 
granisetron and the hydration protocols involving normal 
saline, mannitol, potassium and magnesium 
supplementation are included in the form to minimize the 
risk of missing necessary drugs. Infusion of monoclonal 
antibodies would include the relevant pre-medication such 
as corticosteroids, antihistamine and antipyretic to prevent 
anaphylactic or infusion reactions. Standardized forms 
have also been made specifically for intrathecal 
chemotherapy and only certain anti-cancer drugs which 
can be given by this route are permitted to be printed on 
these forms. 
 
As more oral anti-cancer drugs are being developed, 
optimal treatment outcome becomes dependent on 
patient drug adherence. OPs are in a good position to 
educate patients on the importance of drug adherence 
on the treatment outcome and identify patients’ concerns 
that would potentially dampen drug adherence. [32-35]. 
Equipped with professional drug knowledge, OPs are able 
to address any drug-drug and drug-food interactions and 
advise on the possible management. Drug-drug 
interactions between oral tyrosine kinase inhibitors (TKIs) 
such as gefitinib and erlotinib and gastric acid suppressants 
like proton pump inhibitors (PPI) and histamine-2 receptor 
antagonist (H2RA) are well documented and with clinical 
significance. Patients may require the gastric acid 
suppressants to treat gastrointestinal conditions such as 
gastric ulcer and prevent gastrointestinal complications 
induced by NSAIDs or steroid use. However, gastric acid 
suppressants may increase the gastric pH and lead to 
decreased bioavailability of TKIs. [36-38] By understanding 
patient’s usual time of drug administration, OPs suggest the 
time schedule for taking TKIs that would minimize the 
potential drug-drug interactions. OPs also examine the 
chronic medications which the patients are taking may be 
affected by the chemotherapy and its associated drugs. 
Patients who would proceed to transarterial 
chemoembolization (TACE) in hepatocellular carcinoma 
(HCC) may receive IV contrast during the course of 
treatment. OPs would remind the doctors and patients to 
temporarily withhold metformin to prevent contrast-
induced nephropathy. Patients would be instructed to stop 
combination drugs which contain metformin as well.   
 
MONITORING AND EVALUATION 
Monitoring and evaluating drug therapy has long been a 
focusing area that clinical pharmacists can aid to optimize 
pharmacological therapy. Oncology pharmacists play a 
critical role in assessing patient’s conditions before further 
continuing chemotherapy. OPs monitor complete blood 
picture, renal function and liver function in all patients 
receiving anti-cancer therapy and ensure parameters are 
within acceptable limits to proceed to the next cycle of 
chemotherapy. OPs may also advise the appropriate dose 
reduction in cases of changing renal and liver functions 
and altered body surface area due to significant weight 
changes. In patients receiving trastuzumab, OPs also 
monitor for multigated acquisition scan (MUGA) that 
measures ejection fraction and may remind physicians to 
order routine monitoring and temporarily withhold therapy 
if necessary. [39] Alanine transaminases (ALT) level is 
monitored in patients receiving tyrosine kinase inhibitors 
(TKIs) to observe for possible TKI-induced liver injury. Regular 
monitoring of 24-hour urine protein level before and during 
treatment of bevacizumab by OPs to ensure the patients 
are suitable to receive the treatment and prevents 
worsening of proteinuria after initiation of treatment. 
 
OPs’ assessment and evaluation of a patient’s tolerability 
to previous cycles of chemotherapy can aid physicians in 
prescribing supportive care medicines and make slight 
adjustment to drug therapy. OPs may recommend 
prescribing pre-medication and lengthening infusion time 
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in patients who experienced infusion-related reactions in 
previous cycles of chemotherapy. Besides, OPs may also 
identify episodes of nausea and vomiting in patients 
receiving chemotherapy with low emetogenic potential 
and make interventions on the use of anti-emetics. By 
assessing the tolerability and current performance status, 
OPs are always able to recommend appropriate 
interventions to optimize anticancer treatment. 
 
PATIENT EDUCATION 
Patient empowerment is one of the key components of 
successful cancer treatment. In Hong Kong, OPs deliver 
education through two main methods – patient education 
talks and one-to-one patient counselling. OPs conduct 
education talks in groups, covering fundamental 
knowledge of diseases, common anti-cancer drugs and 
their possible adverse effects and management methods. 
These talks also provide a platform for both patients who 
are new to chemotherapy and those who are already on 
chemotherapy to share their own experience and 
concern. At the same time, OPs would advise on some 
frequently-asked enquiries. By carrying out one-to-one 
patient counselling, OPs are able to educate both the 
patients and their caregivers about the appropriate use 
and the intention of anti-cancer treatment. Particular 
advice on the use of supportive care medications and any 
patient expectations would also be addressed in direct 
counselling. In our hospital, OPs would prepare patient 
information leaflets for oral anti-cancer drugs to facilitate 
patient understanding. By counteracting patients’ 
misconceptions prior to therapy, OPs can successfully 
enhance patient adherence and optimize anti-cancer 
treatment.  
 
Supportive care is one aspect that OPs could play an 
important role. This involves the use of anti-emetics to 
prevent chemotherapy-induced nausea and vomiting, the 
use of granulocyte-colony stimulating factors (GCSF) and 
antibiotics to prevent chemotherapy-induced neutropenic 
fever and certain pre-medications for chemotherapy such 
as pemetrexed and docetaxel. Since these medications 
usually have particular administration schedule, OPs would 
provide corresponding recommendation to facilitate 
patient administration. Besides, OPs would recommend 
patients to take steroid with famotidine to prevent 
gastrointestinal complications and at appropriate time to 
prevent sleep disturbances. Patients who will receive highly 
emetogenic chemotherapy are prescribed with aprepitant 
and require particular advice on the schedule and 
administration time prior to treatment. For patients 
receiving irinotecan, acute and chronic cholinergic 
adverse effects are common and may cause patient harm 
if not well managed, especially diarrhoea. These patients 
are educated by OPs to identify those acute cholinergic 
symptoms during administration and to manage diarrhoea 
by loperamide at home. Patients are also instructed to 
withhold capecitabine themselves if they experience 
grade 2 or more severe adverse reactions to minimize 
toxicity.  
 
Through educating patients to avoid certain food such as 
grapefruit, drug-food interactions with some TKIs such as 
gefitinib and erlotinib can be reduced and the possibility of 
adverse effects can then be minimized. Besides, patients 
who are taking gefitinib and erlotinib are also discouraged 
to use over-the-counter gastric acid suppressants to avoid 
drug-drug interactions. 
 
Various factors have been shown to negatively affect the 
drug adherence in cancer patients including therapy-
related adverse effects. [40-41] The role of OPs in educating 
the management of potential adverse effects is thus 
essential to optimal treatment outcome and better quality 
of life. Dermatological reactions can be present in 
chemotherapy, oral targeted therapy as well as 
immunotherapy and result in significant disturbance to the 
patient. These include but not limited to papulopustular 
rash, hand-foot skin reaction, hand-foot syndrome and 
paronychia. OPs can provide skin care education such as 
decreasing exposure to hot water, friction, avoidance of 
tight-fitting shoes and advice on the appropriate use of 
moisturizers, creams if necessary.  
 
IMPACT OF ONCOLOGY PHARMACISTS ON 
VARIOUS PARTIES 
Oncology pharmacy service receives great appreciation 
from patients, oncologists and other healthcare 
professionals. Patients value oncology pharmacy service as 
a means to medication safety and improved quality of 
cancer therapy. [42-43] Besides, oncology pharmacists 
serve as an information provider and the bridge between 
patients and oncologists. [42] Oncologists also value OPs as 
important team members and are satisfied with the 
improved treatment quality and safety brought by OPs. 
Nurses also consider OPs as important partners in improving 
medication safety and evaluating and managing adverse 
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drug reactions. [42, 44] OPs can also reduce workload from 
nurses and oncologists and aid in better patient follow-up 
and monitoring. Cost is also saved with the input of OPs. [45] 
The positive ratings from different parties confirmed the 
beneficial service by OPs.  
 
CONCLUSION 
Oncology pharmacists are vital members of the 
multidisciplinary team in local hospitals of HK by offering a 
variety of services related to medication management to 
cancer patients. From selection, prescribing, procurement 
to monitoring and education, oncology pharmacists 
contribute heavily to ensure the safe and effective use of 
anti-cancer drugs in any circumstances. Their professional 
drug knowledge adds value to the multidisciplinary team 
and promotes rational use of anti-cancer treatment which 
are highly recognized by other health care professionals. 
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